-
Company Insights
New![]()
Innovation and Patenting activity of CKD Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CKD Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-331 in Hypercholesterolemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-331 in Hypercholesterolemia Drug Details: CKD-331 is under development for the treatment of hypertension and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-385 in Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-385 in Hypertension Drug Details: CKD-385 is under development for the treatment of hyperlipidemia, hypertension,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-331 in Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-331 in Hypertension Drug Details: CKD-331 is under development for the treatment of hypertension and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-331 in Hyperlipidemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-331 in Hyperlipidemia Drug Details: CKD-331 is under development for the treatment of hypertension and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-331 in Hypercholesterolemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-331 in Hypercholesterolemia Drug Details: CKD-331 is under development for the treatment of hypertension and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-516 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CKD-516 in Solid Tumor Drug Details: CKD-516 (NOV-120401) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-385 in Chronic Stable Angina
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-385 in Chronic Stable Angina Drug Details: CKD-385 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-385 in Idiopathic (Essential) Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CKD-385 in Idiopathic (Essential) Hypertension Drug Details: CKD-385 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-371 in Type 2 Diabetes
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CKD-371 in Type 2 Diabetes Drug Details:CKD-371 is under development for the treatment of type 2...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.